SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Monogram Orthopaedics, Inc. MGRM NASDAQ

NASDAQ Capital Marke • Healthcare • Medical - Devices • US • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Analyst Price Target

Monogram Orthopaedics, Inc. (MGRM) is a Medical - Devices company in the Healthcare sector, currently trading at $6.00. It has a SharesGrow Score of 44/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Analyst consensus target is MGRM = $5 (-10% upside).

Net income is $16M (loss), growing at -11.7%/yr. Net profit margin is 0% (thin). Gross margin is 100% (+73 pp trend).

Balance sheet: total debt is $364,000 against $15M equity (Debt-to-Equity (D/E) ratio 0.03, conservative). Current ratio is 10.57 (strong liquidity). Debt-to-assets is 2%. Total assets: $18M.

Analyst outlook: 1 / 1 analysts rate MGRM as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 35/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 50/100 (Partial), Future 74/100 (Pass), Income ?/100 (Fail).

$5.40

▼ 10% Downside

Average Price Target

The 12-month price target for Monogram Orthopaedics, Inc. is $5.40.

MGRM SharesGrow Score Overview

55/100

SharesGrow Score

Above average fundamentals

View full scorecard →

VALUE 35/100

Valuation — P/E, PEG, Forward PEG

GROWTH 15/100

Financials — average growth

PAST 0/100

strong — trend

HEALTH 100/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 50/100

Gross margin is + market cap

FUTURE 74/100

Analyst outlook — as buy

INCOME 0/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — MGRM

MGRM trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $5, implying -16.7% from the current price $6. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.

View details →

MGRM: -100%/yr revenue is, -11.7%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

No analyst coverage available for this stock.

Balance sheet MGRM: Debt-to-Equity (D/E) ratio 0.03 (conservative), Current ratio is 10.57 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

MGRM: Gross margin is 100% (+73 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 50/100. ≥ 70 = Pass.

View details →

Analyst outlook: 1 / 1 analysts rate MGRM as buy (100%). Analyst consensus target is $5 (-16.7% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

No analyst coverage available for this stock.

Stock Chart & Stats

Market Data

52-Week Range1.918-6.425

Volume1.78M

Avg Volume (30D)409.63K

Market Cap$243.79M

Beta (1Y)0.69

Share Statistics

EPS (TTM)-0.50

Shares Outstanding$32.57M

IPO Date2023-05-18

Employees27

CEOBenjamin Sexson

Financial Highlights & Ratios

EBITDA$-15.9M

Net Income$-16.33M

Operating Income$-15.31M

Total Cash$15.66M

Total Debt$364K

Net Debt$-15.29M

Total Assets$17.77M

Price / Earnings (P/E)-12

Analyst Forecast

1Y Price Target$5.40

Target High$5.40

Target Low$5.40

Upside-10.0%

Rating ConsensusBuy

Analysts Covering1

Buy 100% Hold 0% Sell 0%

Price Target Summary

Company Info

CountryUS

ExchangeNASDAQ Capital Marke

CurrencyUSD

ISINUS6097861081

Price Chart

MGRM

Monogram Orthopaedics, Inc. ↗ · NASDAQ Capital Marke

Healthcare • Medical - Devices

1.92 52WK RANGE 6.43

People Also View

Eli Lilly and Company

Johnson & Johnson

Roche Holding AG

Roche Holding AG

AstraZeneca PLC

Merck & Co., Inc.

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message